CAR-T toxicities are rare after two weeks in diffuse large B-cell non-Hodgkin lymphoma treatment, and shorter restriction periods could increase overall treatment accessibility (WASHINGTON, July 24, 2024) – In patients with diffuse large B-cell non-H...

Study suggests that hydroxyurea alters the developmental process of ovarian follicles, but not their quantity (WASHINGTON, July 18, 2024) — In female patients living with sickle cell disease (SCD), hydroxyurea had no effect on ovarian reserve,...

Findings refute former consensus that pregnancies post-transplant are nearly impossible, highlight need for increased fertility counseling   (WASHINGTON, July 15, 2024) — Despite treatment-related fertility challenges, female patients can become...

Study findings suggest that clear clinician guidance on testing and treatment may save lives (WASHINGTON, June 21, 2024) – Patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas (NHLs) who received frequent tests for immunoglobu...

(WASHINGTON, June 18, 2024) — The American Society of Hematology (ASH) will recognize exemplary hematologists who have made significant contributions to the field with several honorific awards at the 2024 ASH Annual Meeting and Exposition in San Dieg...

Risk of bleeding highest in first three months of treatment, even in patients on low doses of direct oral anticoagulants    (WASHINGTON, June 6, 2024) – Patients with atrial fibrillation (Afib) who took low doses of blood-thinning me...

Health and hospital systems can help pediatric patients transition to adult care to reduce inpatient hospital visits​ (WASHINGTON, May 29, 2024) – Individuals living with sickle cell disease (SCD) who experience a delay of more than six months in tr...

Protective effect seen in all subtypes of myeloproliferative neoplasms (WASHINGTON, May 17, 2024) – People who use metformin are less likely to develop a myeloproliferative neoplasm (MPN) over time, indicating that the treatment may help prevent the...

Standard of care treatment for acute myeloid leukemia extends survival in adults 80 to 90 years old (WASHINGTON, May 9, 2024) – Standard of care treatment for acute myeloid leukemia (AML) is safe and effective for adults over 80, according to a study...

The Real-World Evidence Consortium for Sickle Cell Disease will develop consensus on how to use data collected from electronic health records for research and to improve care (WASHINGTON, April 17, 2024) –The ASH Research Collaborative (ASH RC) and t...